MiNK Therapeutics to Present Three Abstracts on Novel Allogeneic iNKT Programs at SITC
MiNK Therapeutics, a biopharmaceutical company focused on iNKT cell therapies for cancer and immune diseases, has announced the acceptance of three abstracts for the Society for Immunotherapy of Cancer’s 36th Annual Meeting, scheduled for November 10-14, 2021. The presentations will cover AgenT-797, including its persistence, tissue distribution, and anti-tumor activity. Abstracts will be released on November 9, 2021, with data also available on the investor section of their website post-presentation on November 12, 2021.
- None.
- None.
Insights
Analyzing...
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced acceptance of three abstracts for presentation at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting being held between November 10-14, 2021.
Presentation Details:
Abstract title: Persistence and tissue distribution of AgenT-797 – a native allogeneic iNKT cell-therapy drug product (NCT04582201 and NCT04754100)
Abstract number: 400
Presenting author: Marco Purbhoo
Abstract title: AgenT-797, a native allogeneic “off-the-shelf” iNKT cell therapy product shows anti-tumor activity in preclinical xenograft models
Abstract number: 205
Presenting author: Burcu Yigit
Abstract title: Identification and characterization of an allogeneic iNKT-CAR targeting BCMA
Abstract number: 135
Presenting author: Xavier Michelet
The full abstracts will be released on Tuesday, November 9, 2021. The updated data will be presented at the conference and will become available in the investor section of our website at http://investor.minktherapeutics.com following the presentation on November 12, 2021.
About MiNK Therapeutics
MiNK Therapeutics is a clinical stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/ and follow MiNK on LinkedIn and Twitter @MiNK_iNKT.
Contact
MiNK Therapeutics
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
FAQ
What abstracts were accepted for presentation by MiNK Therapeutics at the 2021 SITC Annual Meeting?
When will the full abstracts be released by MiNK Therapeutics?
What is the date of MiNK Therapeutics' presentation at the SITC 2021 conference?
Where can I find the data presented by MiNK Therapeutics after the SITC meeting?
